Goto A, Yamada K
Second Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
Curr Opin Nephrol Hypertens. 1998 Mar;7(2):189-96. doi: 10.1097/00041552-199803000-00008.
Accumulated evidence has suggested that several sodium pump inhibitors, similar to cardiotonic steroids, are present in the human body. Ouabain-like factor, the most appealing candidate, has been found to be increased with high sodium intake and hypervolaemia, and in essential hypertension, mineralocorticoid hypertension, and pregnancy-induced hypertension. Furthermore, blocking the action of ouabain-like factor with digibind or a novel anti-ouabain agent lowers blood pressure in several models of hypertension. Several important questions remain, however, before it can be concluded that ouabain-like factor is indeed involved in the regulation of sodium homeostasis and blood pressure.
越来越多的证据表明，人体内存在几种与强心甾体类似的钠泵抑制剂。哇巴因样因子是最具吸引力的候选物质，已发现其在高钠摄入、血容量过多以及原发性高血压、盐皮质激素性高血压和妊娠高血压中会升高。此外，在几种高血压模型中，用地高辛抗体或一种新型抗哇巴因药物阻断哇巴因样因子的作用可降低血压。然而，在得出哇巴因样因子确实参与钠稳态和血压调节的结论之前，仍有几个重要问题有待解决。
